Indication (pathologie):
Chronic type B viral hepatitis
Identifiant SNOMED-CT:
61977001
Etudes cliniques
-
A first-time-in human (FTIH), Phase I, randomized,multi-centric, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of GSK Biologicals’ HBV viral vector vaccines given in a prime-boost schedule with sequential or co-administration of adjuvanted proteins therapeutic vaccine (GSK3528869A) in chronic Hepatitis B patients (18-65 years old) well controlled under nucleo(s)tides analogues (NA) therapy.Phase de l'étude: Phase IRecrutement: Ouvert
-
Total Motorized Spiral Enteroscopy Trial (TMSET) (étude multicentrique européenne sur l’entéroscopie complète au moyen du nouvel endoscope motorisé à spirale)Indication (pathologie):EnteroscopyIdentifiant SNOMED-CT:235147008Recrutement: Ouvert
-
A prospective study to evaluate the safety and feasibility of an endoluminal-suturing device (ENDOMINA®) as an aid for afferent loop syndrome.Indication (pathologie):Afferent loop syndromeIdentifiant SNOMED-CT:20813000Recrutement: Ouvert
-
Prevention of mortality with long-term administration of human albumin in subjects with decompensated cirrhosis and ascitesIndication (pathologie):Decompensated cirrhosisIdentifiant SNOMED-CT:716203000Indication (pathologie):AscitesIdentifiant SNOMED-CT:389026000Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A phase 3, randomized, double-blind study of adjuvant nivolumab versus placebo for participants with hepatocellular carcinoma who are at high risk of recurrence after curative hepatic resection or ablationIndication (pathologie):Hepatocellular carcinomaIdentifiant SNOMED-CT:109841003Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A multicenter, randomized, double-blind, placebo-controlled induction study to evaluate the efficacy and safety of risankizumab in subjects with moderately to severely active ulcerative colitis who have failed prior biologic therapyIndication (pathologie):Ulcerative colitisIdentifiant SNOMED-CT:64766004Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A multicenter, randomized, double-blind, placebo-controlled 52-week maintenance and an open-label extension study of the efficacy and safety of risankizumab in subjects with ulcerative colitis who responded to induction treatment in M16-067 or M16-065Indication (pathologie):Ulcerative colitisIdentifiant SNOMED-CT:64766004Phase de l'étude: Phase IIIRecrutement: Ouvert
-
Endomina-v2mini-eftr: a prospective study to evaluate the safety and feasibility of an endoluminal suturing device (Endomina-v2mini) as an aid for endoscopic full thickness resectionIndication (pathologie):Endoscopic mucosal biopsy and resection kitIdentifiant SNOMED-CT:714733006Indication (pathologie):Endoscopic submucosal dissection of rectum using colonoscopeIdentifiant SNOMED-CT:713154003Recrutement: Ouvert
-
Protocol endomina–v2mini-diverticulum: A prospective study to evaluate the safety and feasibility of an endoluminal-suturing device (Endomina-v2mini) as an aid for diverticulum treatmentIndication (pathologie):esophageal diverticulumIdentifiant SNOMED-CT:235637006Recrutement: Ouvert
-
A pilot study to evaluate the feasibility and the safety of an enoluminal-suturing device (endomina-v2 mini) as a treatment for GERDIndication (pathologie):Gastro-esophageal refluxIdentifiant SNOMED-CT:235595009Recrutement: Ouvert
-
A first-in-human, double-blind, randomized, placebo-controlled, Phase 1 study to evaluate the safety, tolerability, reactogenicity, and immunogenicity of JNJ-64300535, a DNA vaccine, administered by electroporation-mediated intramuscular injection, in participants with chronic Hepatitis B who are on stable nucleos(t)ide therapy and virologically suppressedIndication (pathologie):Chronic viral hepatitisIdentifiant SNOMED-CT:61977001Phase de l'étude: Phase IRecrutement: Ouvert
-
A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (AMBER)Indication (pathologie):Autoimmune hepatitisIdentifiant SNOMED-CT:408335007Phase de l'étude: Phase IIIRecrutement: Ouvert
-
Universal partially covered removable self-expanding stent and anchoring system for the treatment of refractory benign oesophageal strictures (UAS-RBS): a safety studyIndication (pathologie):Benign oesphageal strictureIdentifiant SNOMED-CT:235616003Recrutement: Ouvert
-
Options thérapeutiques au cours des hépatites B et C - une cohorte nationale françaiseIndication (pathologie):Hépatite CIdentifiant SNOMED-CT:50711007Indication (pathologie):Hépatite BIdentifiant SNOMED-CT:66071002Recrutement: Ouvert
-
Real world evidence of the effectiveness and clinical practice use of glecaprevir plus pibrentasvir in patients with chronic hepatitis C genotypes 1 to 6Indication (pathologie):Hépatite CIdentifiant SNOMED-CT:50711007Phase de l'étude: Phase IVRecrutement: Ouvert
-
Enregistrement prospectif du traitement endoluminal dans le tractus gastro-intestinal.Indication (pathologie):Œsophage de BarrettIdentifiant SNOMED-CT:302914006Recrutement: Ouvert
-
Wide area transepithelial sample esophageal biopsy combined with computer assisted 3-dimensional tissue analysis (WATS) for the detection of high grade esophageal dysplasia and adenocarcinoma: a multi- center prospective, randomized, tandem studyIndication (pathologie):Adénocarcinome œsophagienIdentifiant SNOMED-CT:276803003Indication (pathologie):Dysplasie oesophagienneIdentifiant SNOMED-CT:308857008Recrutement: Ouvert
-
A multicenter, randomized, double-blind, placebo-controlled induction study to assess the efficacy and safety of risankizumab in subjects with moderately to severely active Crohn's disease who failed prior biologic treatment (15-991)Indication (pathologie):Crohn’s diseaseIdentifiant SNOMED-CT:3400006Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A multicenter, randomized, double-blind, placebo-controlled induction study of the efficacy and safety of risankizumab in subjects with moderately to severely active Crohn's disease (M16-006)Indication (pathologie):Crohn’s diseaseIdentifiant SNOMED-CT:3400006Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A phase III, randomized, double-blind, clinical trial of pembrolizumab (MK-3475) plus chemotherapy (XP or FP) versus placebo plus chemotherapy (XP or FP) as neoadjuvant/adjuvant treatment for subjects with gastric and gastroesophageal junction (GEJ) adenocarcinoma (KEYNOTE-585)Indication (pathologie):AdenocarcinomaIdentifiant SNOMED-CT:443961001Phase de l'étude: Phase IIIRecrutement: Ouvert